Halabi Inducted as SCT Fellow

Susan Halabi, PhD, professor of Biostatistics and Bioinformatics, was recently inducted as a 2014 fellow to the Society for Clinical Trials (SCT). In its citation, the SCT recognized Halabi for her “outstanding leadership in cancer clinical trials and prognostic development, her educational activities and dedicated service.”

Established 36 years ago, the SCT is an international professional organization dedicated to the development and dissemination of knowledge about the best practices in the design, conduct, analysis and reporting of clinical trials. The organization is made up of clinical trialists from government, academia, industry and non-profit organizations.

Membership consists of clinicians, statisticians, behavioral scientists, computer scientists, clinical research associates and coordinators, data managers, information technology specialists, research nurses, pharmacologists, health economists, project managers and ethicists. Members share a common desire to learn, while advancing the field of clinical trials methodology.

Halabi is the co-editor of Oncology Clinical Trials, Successful Design, Conduct and Analysis, a guide for junior faculty members conducting a clinical trial for the first time. Proceeds from the book are donated to a non-profit fund for young investigators for the Conquer Cancer Foundation.

Halabi’s passion for cancer research developed when, while completing her doctoral work, her best friend was diagnosed with a fatal form of breast cancer. Her work at the DCI includes clinical trials focused on prostate, bladder  and renal cancers. Halabi developed  several nomograms for calculating probability of survival among patients battling prostate cancer. These multivariable tools assist in making life-altering decisions related to treatment and patient selection in clinical trials.

“It is a great honor and a privilege to receive this award, which is a recognition for outstanding professional contributions to the scientific community and leadership in clinical trials in genitourinary cancers,” Dr. Halabi said.

On another note, on June 1, Halabi presented at the American Society of Clinical Oncology. Her abstract on survival rates in castration-resistant prostate cancer (CRPC) was featured in the 2014 meeting of the American Society of Clinical Oncology. To read Dr. Halabi’s abstract or watch her ASCO interview, click here. To learn more about the Society of Clinical Trials or to apply for membership, visit http://www.sctweb.org.